EPC Live Program 9.07.25

Clinical Update for Non-Cystic Fibrosis Bronchiectasis: Strategies to Manage Exacerbations and Lung Function
Supported by an independent education grant from Insmed

a. Chronic cough, mucus production, and respiratory infectionsb. High-resolution CT imaging of the chest demonstrating bronchial dilationc. Based on clinical presentation, specific testing for possible causes of bronchiectasis should be performedd. Regardless of cause of bronchiectasis, a trial of airway clearance should be tried on all patientse. All of the above

a. Oral azithromycin 500mg PO dailyb. Prednisone 10mg PO dailyc. Inhaled Tobramycin solution 300mg twice daily every other monthd. Brensocatib 25mg PO dailye. No change in therapy

Update on Long-Acting Nebulizers for Guideline-Based Maintenance Treatments for Patients with COPD
Supported by an independent education grant from Viatris Specialty LLC

Therapeutic Update on COPD with Type 2 Inflammation
Supported by an independent education grant from GSK

a. 1 in 20b. 1 in 10c. 1 in 5d. 1 in 3

a. Monotherapy with a bronchodilatorb. Monotherapy with a long-acting beta-2 agonist (LABA)c. Monotherapy with a long-acting muscarinic antagonist (LAMA)d. Combination therapy with LABA+LAMA

a. ~10% in patients with COPD and high blood eosinophil phenotypeb. ~21% in patients with COPD and high blood eosinophil phenotypec. ~10% in patients with COPD regardless of blood eosinophil leveld. ~33% in patients with COPD regardless of blood eosinophil level

Clinical Update for Non-Cystic Fibrosis Bronchiectasis: Strategies to Manage Exacerbations and Lung Function
Supported by an independent education grant from Insmed

a. Oral azithromycin 500mg PO dailyb. Prednisone 10mg PO dailyc. Inhaled Tobramycin solution 300mg twice daily every other monthd. Brensocatib 25mg PO dailye. No change in therapy

Update on Long-Acting Nebulizers for Guideline-Based Maintenance Treatments for Patients with COPD
Supported by an independent education grant from Viatris Specialty LLC

Therapeutic Update on COPD with Type 2 Inflammation
Supported by an independent education grant from GSK

a. 1 in 20b. 1 in 10c. 1 in 5d. 1 in 3

a. Monotherapy with a bronchodilatorb. Monotherapy with a long-acting beta-2 agonist (LABA)c. Monotherapy with a long-acting muscarinic antagonist (LAMA)d. Combination therapy with LABA+LAMA

PulmonologistPrimary CareOther

Private PracticeHospitalAcademicOther

Please rate the extent to which this activity met the following objectives:

Rows	Poor	Fair	Good	Very Good	Excellent
Review the current clinical trial data for therapeutic options to manage NCFBE
Analyze clinical strategies to apply the most appropriate therapeutic options to improve outcomes for patients with NCFBE
Review the updated 2025 GOLD guidelines for the management of patients with moderate-to-severe COPD and their implications for guideline-driven care
Analyze current clinical trial data for LAMA nebulizer therapeutic options to manage COPD
Review clinical strategies to apply guideline- driven long-acting nebulizer treatments for the maintenance of patients with moderate-to-severe COPD
Describe updates to the latest iteration of GOLD guidelines that outline optimal diagnostic and treatment procedures for individuals with type 2 eosinophilic COPD
Assess the efficacy, safety, and mechanisms of action of newly approved and emerging pharmacotherapy for patients with type 2 eosinophilic COPD
Select the most appropriate therapeutic strategy for patients with type 2 eosinophilic COPD on the basis of relevant clinical factors

Rows	Poor	Fair	Good	Very Good	Excellent
Overall Program
Content
Usefulness

Rows	Poor	Fair	Good	Very Good	Excellent
Jeffrey Hoag, MD
Nicola Hanania, MD

I gained new strategies/skills/information that my team can apply to practiceI plan to implement new strategies/skills/information in my practiceI will be more competent in my team’s management of patient careI will improve my communication with the healthcare team

Attestation: This activity is certified for a maximum of 1.5 AMA PRA Category 1 Credits™.

PRE-TEST QUESTIONNAIRE

POST-TEST ASSESSMENT